Regeneron Pharmaceuticals, Inc. (REGN) Earnings Call Transcripts
Regeneron Pharmaceuticals, Inc.'s Latest Earnings Call - Q2 FY2026
In the second quarter of 2026, Regeneron Pharmaceuticals reported total revenues of $4.3 billion, reflecting a 17% year-over-year increase, driven primarily by strong sales of Dupixen, EYLEA HD, and Libtayo. Non-GAAP earnings per share grew 11% to $14.29, despite a $0.99 negative impact from acquired in-process research and development expenses. Management maintained a positive outlook, signaling continued growth momentum and potential for increased collaboration revenue following the repayment of the Sanofi development balance.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $4.3B (beat) |
| EPS | $14.29 (beat) |
| Dupixen Sales | $6B (beat) |
| EYLEA HD Sales | $600M (beat) |
| Sanofi Collaboration Revenue | $2.2B (beat) |
| Libtayo Sales | $489M (beat) |
Guidance from management
Management maintained a positive outlook for the second half of 2026, expecting continued growth in Dupixen and EYLEA HD, while anticipating a moderation in growth rates due to stronger prior year comparisons.
What management said
Thank you, Chris. This concludes our prepared remarks. We will now open the call for Q&A. I'm sure we are able to address as many questions as possible, we will answer one question from each caller before moving to the next.
And when you asked about development and expediting it. We should just remind you we have led the most innovative development program, probably in the history of the industry in terms of with Dupixen getting it approved for 9 different indications, including many of them, the first approved biologic in many of these indications. Obviously, we know this field, we created field better than anyone else. And just as we'v...
What analysts pressed on
Analysts expressed concerns regarding the competitive dynamics affecting EYLEA sales and the potential impact of upcoming biosimilar launches. There were also questions about the sustainability of Dupixen's growth trajectory given the increasing competition in the immunology space.
Main topics on the call
- Dupixen Sales Growth — Dupixen achieved net sales of $6 billion in the second quarter, marking a 38% increase year-over-year on a constant currency basis. Management noted, "Demand trends across all approved indications remained robust and acc...
- EYLEA HD Performance — EYLEA HD net sales reached nearly $600 million, a 52% increase compared to the prior year. This quarter marked the first time EYLEA HD sales exceeded those of EYLEA, indicating strong market adoption and physician demand...
- Pipeline Advancements — Regeneron highlighted progress in its pipeline, with multiple upcoming milestones, including an FDA decision for cemdisiran in November. Management emphasized, "We have one of the largest R&D portfolios in the entire ind...
- Sanofi Collaboration Revenue — Sanofi collaboration revenue reached an all-time high of $2.2 billion, with Regeneron's share of profits growing 59% year-over-year. Management expects collaboration revenue to increase further following the repayment of...
Read the full Regeneron Pharmaceuticals, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 134 calls on record spanning January 13, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 134 Regeneron Pharmaceuticals, Inc. earnings call transcripts on record, spanning January 13, 2020 to July 30, 2026. Based on this history, Regeneron Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- REGN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 134
- First call
- January 13, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly